Protara Therapeutics, Inc. (TARA)

Market Cap	274.21M +64.3%
Revenue (ttm)	n/a
Net Income	-57.44M
EPS	-1.34
Shares Out	54.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	463,284
Open	5.00
Previous Close	4.96
Day's Range	4.93 - 5.15
52-Week Range	2.77 - 7.82
Beta	1.50
Analysts	Strong Buy
Price Target	21.67 (+327.42%)
Earnings Date	May 7, 2026

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jesse Shefferman
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: TARA
• Website: https://www.protaratx.com

Analyst Summary

According to 6 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price target is $21.67, which is an increase of 327.42% from the latest price.

Price Target

$21.67

(327.42% upside)

Analyst Consensus: Strong Buy